Cancers, Vol. 16, Pages 1545: Prices and Trends in FDA-Approved Medications for Sarcomas

Cancers, Vol. 16, Pages 1545: Prices and Trends in FDA-Approved Medications for Sarcomas Cancers doi: 10.3390/cancers16081545 Authors: Caleb Hwang Mark Agulnik Brian Schulte Sarcomas represent a diverse set of both malignant and benign subtypes consisting of often rare and ultra-rare conditions. Over the course of the last decade, there have been numerous FDA approvals for agents treating various sarcoma subtypes. Given this burgeoning landscape of sarcoma treatments, we seek to review current FDA-approved agents with respect to their rates of incidence, approval rates, and financial costs. We gathered clinical trial data by searching FDA approval announcements from 2013 to 2023. We determined the 30 day and one year cost of therapy for patients of FDA-approved sarcoma treatments in the aforementioned timeframe. From 2013 to 2023, 14 medications have been FDA-approved for sarcoma subtypes. The 30-day dosing prices for these medications range from $11,162.86 to $46,926.00. Since 2013, the rates of approval for sarcoma medications have been higher than in prior decades. Nonetheless, there remains the potential for significant financial toxicity for patients living with sarcoma.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research